Tisotumab Vedotin

3 trials NNeurology/Psychiatry

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

0 Recruiting

3 Completed trials

2 Sponsors

14 Countries

Phase III

Phase II

Phase I/II

Phase III: 1 Phase II: 1 Phase I/II: 1

Indications tested

Cervix carcinoma 2 Non-small cell lung cancer metastatic 1 Pancreatic carcinoma metastatic 1 Head and neck cancer metastatic 1 Non-small cell lung cancer 1 Pancreatic carcinoma 1 Colorectal cancer stage IV 1 Non-small cell lung cancer stage IV 1 Pancreatic neoplasm 1 Colorectal cancer metastatic 1 Head and neck cancer stage IV 1 Non-small cell lung cancer stage IIIB 1

Sponsors using this IMP

Seagen Inc. 2 Genmab A/S 1

All trials

3 total

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors Ended

2023-503812-34-00 Phase II 4 countries Seagen Inc.
A Randomized, Open-Label Trial to Compare Tisotumab Vedotin to Investigator's Choice Chemotherapy in Patients with Cervical Cancer Ended

2023-503813-31-01 Phase III 13 countries Seagen Inc.
Efficacy and safety of tisotumab vedotin (HuMax®-TF-ADC) monotherapy and in combination in recurrent or Stage IVB cervical cancer Ended

2023-508832-68-00 Phase I/II 6 countries Genmab A/S

Showing 1–3 of 3 trials

← All drugs A–Z